Given these trial results, there remains uncertainty about emraclidine’s future prospects and AbbVie’s ability to present a competitive alternative in the schizophrenia treatment market, particularly ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.
BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more ...
Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Related: Bristol Myers's stock pops as earnings top estimates and company raises guidance In September, Bristol Myers's shares rose after the FDA approved Cobenfy. The drug, previously called KarXT, ...
Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
Investing.com - AbbVie (NYSE: ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia ...
Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15%Net cash provided by operating activities of $704 millionCapital ...
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
Cobenfy, improved disease symptoms with a well-tolerated safety profile over 12 months across two Phase 3 trials. In September, the FDA approved the drug previously known as KarXT as a novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback